Green Cross Holdings Corporation (KRX:005250)
South Korea · Delayed Price · Currency is KRW 16,010
+630 (4.10%)
At close: Nov 26, 2025
Green Cross Holdings Revenue
Green Cross Holdings had revenue of 736.86B KRW in the quarter ending September 30, 2025, with 20.80% growth. This brings the company's revenue in the last twelve months to 2.40T, up 9.89% year-over-year. In the year 2024, Green Cross Holdings had annual revenue of 2.20T with 7.14% growth.
Revenue (ttm)
2.40T
Revenue Growth
+9.89%
P/S Ratio
0.30
Revenue / Employee
16.65B
Employees
144
Market Cap
726.88B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.20T | 146.92B | 7.14% |
| Dec 31, 2023 | 2.06T | -21.62B | -1.04% |
| Dec 31, 2022 | 2.08T | 239.00B | 12.99% |
| Dec 31, 2021 | 1.84T | 121.23B | 7.05% |
| Dec 31, 2020 | 1.72T | 225.74B | 15.11% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.50T |
| Celltrion | 3.90T |
| Yuhan | 2.17T |
| Hanmi Pharm. | 1.47T |
| SK Biopharmaceuticals | 675.41B |
| Sam Chun Dang Pharm. | 215.10B |
| ALTEOGEN | 158.06B |
| LigaChem Biosciences | 148.28B |
Green Cross Holdings News
- 22 days ago - MedGenome Makes a Majority Investment in Leading Gujarat-Based Diagnostics Chain Green Cross to Expand Genomics Offerings Across India - Business Upturn